Sanofi completes acquisition of Inhibrx, Inc. to enhance rare disease pipeline
May 30, 2024•over 1 year ago
Acquiring Company
Sanofi
Acquired Company
Inhibrx
Paris
San DiegoPharmaceuticalMedicalBiotechnologyHealth CareBiotechnologyBiopharmaTherapeuticsDescription
Sanofi has successfully completed its acquisition of Inhibrx, Inc. The acquisition adds SAR447537 to Sanofi’s rare disease pipeline, aiming to provide better treatment options for AATD patients and strengthen Sanofi’s capabilities in the healthcare sector.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed